Applied Genetic Technologies (AGTC) Prices 6.5M Share Common Offering at $5/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Applied Genetic Technologies Corp. (AGTC) PT Raised to $10 at Chardan Capital Markets
February 6, 2020 12:10 PM ESTChardan Capital Markets analyst Gbola Amusa raised the price target on Applied Genetic Technologies Corp. (NASDAQ: AGTC) to $10.00 (from $7.50) while maintaining a Buy rating.
... MorePre-Open Stock Movers 02/06: (UIS) (FSCT) (LDOS) Higher (TNXP) (RWLK) (FNKO) Lower (more...)
February 6, 2020 9:24 AM ESTPre-Open Stock Movers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) 56.5% LOWER; announced today that the Company has decided to stop enrollment in the Phase 3 RECOVERY study of Tonmya# or TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD) following an unblinded, pre-specified interim analysis by the Independent Data Monitoring Committee (IDMC). Based on interim analysis results of the first 50% of enrolled participants, the IDMC recommended stopping the trial for futility as Tonmya is unlikely to demonstrate a statistically significant improvement in the... More
After-Hours Stock Movers 02/05: (SONO) (ELF) (ZNGA) Higher; (TNXP) (FNKO) (GPRO) Lower (more...)
February 5, 2020 6:00 PM ESTAfter-Hours Movers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) 64.7% LOWER; announced today that the Company has decided to stop enrollment in the Phase 3 RECOVERY study of Tonmya# or TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD) following an unblinded, pre-specified interim analysis by the Independent Data Monitoring Committee (IDMC). Based on interim analysis results of the first 50% of enrolled participants, the IDMC recommended stopping the trial for futility as Tonmya is unlikely to demonstrate a statistically significant improvement in the primary... More
Applied Genetic Technologies (AGTC) Announces Proposed 6M Share Public Offering of Common Stock
February 5, 2020 4:37 PM ESTApplied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All the shares in the offering will be sold by AGTC. In addition, AGTC expects to grant the underwriters a 30-day option to purchase up to... More
